Actively Recruiting
64Cu-LLP2A for Imaging Hematologic Malignancies
Led by Washington University School of Medicine · Updated on 2025-07-31
42
Participants Needed
1
Research Sites
109 weeks
Total Duration
On this page
Sponsors
W
Washington University School of Medicine
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.
CONDITIONS
Official Title
64Cu-LLP2A for Imaging Hematologic Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Able to give informed consent
- Able to understand and follow study instructions
- Capable of lying still and flat in a PET/CT scanner for up to 75 minutes
- No illicit or inhaled drug use in the past year (self-reported)
- No history of claustrophobia or conditions interfering with imaging sessions
- Not currently pregnant or nursing; must be surgically sterile, post-menopausal, non-lactating, or have a negative pregnancy test within 24 hours before drug administration
- For patients: confirmed diagnosis of multiple myeloma or low-grade lymphoma (including follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma, or chronic lymphocytic leukemia)
- Patients may be newly diagnosed, relapsed, refractory, or post bone marrow transplant with negative imaging and suspected recurrence
- Patients participating in other imaging or therapeutic trials with investigational agents are eligible
You will not qualify if you...
- Currently pregnant or nursing without meeting sterilization, menopause, or negative pregnancy test criteria
- History of claustrophobia or other conditions that prevent completion of imaging sessions
- Illicit or inhaled drug use in the past year
- Inability to lie still and supine during PET/CT scans
- Unable to provide informed consent or follow study procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
F
Farrokh Dehdashti, M.D.
CONTACT
J
Jennifer Frye, CNMT, CCRC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here